Life Science Investing NRx Pharmaceuticals announces elimination of all balance sheet debt following equity conversion
Life Science Investing NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
Life Science Investing NRx Pharmaceuticals Announces US Food and Drug Administration Receipt of ANDA for KETAFREE, a Preservative-Free IV Ketamine
Life Science Investing NRx Pharmaceuticals and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference
Life Science Investing NRx Pharmaceuticals, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing NRx Pharmaceuticals, Inc. to Report Third Quarter 2025 Financial Results on November 17, 2025
Life Science Investing HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day Depression Treatment in Partnership with Ampa Health
Life Science Investing HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
Life Science Investing NRx Pharmaceuticals, Inc. to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference
Life Science Investing NRx Pharmaceuticals, Inc. Re-Files Abbreviated New Drug Application for KETAFREE, Preservative-Free IV Ketamine
Life Science Investing NRx Pharmaceuticals, Inc. Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine
Life Science Investing HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics
Life Science Investing NRx Pharmaceuticals to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th
